Heated chemo plus immunotherapy shows promise for tough ovarian cancers
NCT ID NCT03959761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the immunotherapy drug nivolumab directly into the abdomen is safe after extensive surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. 22 adults with recurrent ovarian, peritoneal, or fallopian tube cancer took part. The goal was to find the best dose that does not cause severe side effects, while potentially boosting the immune system's ability to fight remaining cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospices Civils de Lyon
Lyon, 69002, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?